<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We tested the abilities of two potent non-<z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> (non-<z:chebi fb="0" ids="31882">NMDA</z:chebi>) <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> [2,3-dihydroxy-6-<z:chebi fb="13" ids="29785">nitro</z:chebi>-7-sulfamoylbenzo(F)<z:chebi fb="0" ids="36616">quinoxaline</z:chebi> (NBQX)] and [1-(4-aminophenyl)-4-<z:chebi fb="36" ids="29309">methyl</z:chebi>-7,8-<z:chebi fb="13" ids="29357,29358">methylene</z:chebi>-dioxy-5H-2,3-benzodiazep ine <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> (GYKI 52466)] to reduce neocortical infarction following 2 h of transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in a hypertensive <z:hpo ids='HP_0001297'>stroke</z:hpo> model in the rat and compared these effects against, and in combination with, a potent <z:chebi fb="0" ids="31882">NMDA</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi> [(+)-5-<z:chebi fb="36" ids="29309">methyl</z:chebi>-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-<z:chebi fb="39" ids="32952">amine</z:chebi> maleate (MK-801)] </plain></SENT>
<SENT sid="1" pm="."><plain>In Expt </plain></SENT>
<SENT sid="2" pm="."><plain>1, an already established cytoprotective dose of <z:chebi fb="0" ids="29101">Na(+)</z:chebi>-NBQX (30 mg/kg i.p. x 3) was compared with saline (1 ml), the <z:chebi fb="0" ids="31882">NMDA</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi> MK-801 (1 mg/kg i.p. x 3), and a combination of the same doses of both NBQX and MK-801 </plain></SENT>
<SENT sid="3" pm="."><plain>Initial doses were delayed to 90 min following occlusion with subsequent injections at the time of reperfusion and 30 min following reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain>Saline-treated rats sustained 181 +/- 32 mm3 (n = 15) of neocortical infarction (mean +/- SD) </plain></SENT>
<SENT sid="5" pm="."><plain>This was significantly reduced by NBQX to 137 +/- 25 mm3 (n = 15, p &lt; 0.05) of damage </plain></SENT>
<SENT sid="6" pm="."><plain>Neither MK-801 (170 +/- 33 mm3; n = 11) nor the combination of MK-801 and NBQX (169 +/- 20 mm3; n = 6) proved to be cytoprotective when given with a 90-min delay </plain></SENT>
<SENT sid="7" pm="."><plain>In Expt </plain></SENT>
<SENT sid="8" pm="."><plain>2, NBQX (30 mg/kg) was dissolved (6 mg/ml) in 5% <z:chebi fb="10" ids="4167">dextrose</z:chebi> and compared with both saline and <z:chebi fb="10" ids="4167">dextrose</z:chebi> (1.2 ml) i.v. infusions given over a 4-h period starting 1 h after occlusion </plain></SENT>
<SENT sid="9" pm="."><plain>Saline-treated rats had a mean <z:mpath ids='MPATH_124'>infarct</z:mpath> of 183 +/- 27 mm3 (n = 6), <z:chebi fb="10" ids="4167">dextrose</z:chebi>-treated had 200 +/- 30 mm3 (n = 9), while for NBQX-treated rats it was reduced to 129 +/- 60 mm3 (n = 10, p &lt; 0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>Intravenous NBQX precipitated into the renal tubules, causing nephrotoxicity </plain></SENT>
<SENT sid="11" pm="."><plain>In Expt </plain></SENT>
<SENT sid="12" pm="."><plain>3, rats were given either saline (1 ml i.p.) or GYKI 52466 (10 mg/kg i.p.) at 30 and 90 min following occlusion and at 30, 90, and 150 min following reperfusion </plain></SENT>
<SENT sid="13" pm="."><plain>Saline-treated rats sustained 187 +/- 27 mm3 of neocortical infarction (n = 7), while those treated with GYKI 52466 were protected, with 139 +/- 38 mm3 of infarction (n = 7, p &lt; 0.05) </plain></SENT>
<SENT sid="14" pm="."><plain>A clinically useful role for alpha-amino-3-hydroxy-5-<z:chebi fb="36" ids="29309">methyl</z:chebi>-4-<z:chebi fb="0" ids="35595">isoxazole</z:chebi> <z:chebi fb="0" ids="17272">propionate</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> in embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> is envisaged if nontoxic drugs can be developed, since cerebroprotection was achieved with delayed treatment with both of these <z:chebi fb="3" ids="33585">lead compounds</z:chebi> </plain></SENT>
</text></document>